Product Design
Memo (re: report on the psychopharmacological effects of the N'-substituted nicotine analogues)
Abstract
Memo describes results of a study on psychopharmacologic effects of N'-substituted nicotine analogues. Compunds were found to produce mild sedation and muscle relaxation in rats, although not depressants, and "might be of value in anxiety-related depression. Recommedation to consider applying for patents for this chemically unique class of compounds.
Fields
- Rank
- 1
- Author
- ABOOD, LG
- Hypothesis
- Health effectsDesign changes which have measurably altered health effects of cigarette smoke, both for smokers and nonsmokers.
- Nicotine transport, transfer, and uptakeDesign changes which alter nicotine delivery or effect how the product causes and maintains dependence, including transfer of nicotine from tobacco to smoke, and uptake into the body.
- Keyword
- Depressants
- Muscle relaxant
- Psychotherapeutic
- Tranquilizers
- Additive
- N'-substituted nicotine analogues
- Smoke Constituent
- Benzodiazepines
- Subject
- CNS/Brain (Effects)
- nicotine technology
- nicotine analogues (Technology)
- Pharmacology (Effects)
Document Images
~.
March 16, 1983
T. S. Osdene, Ph.D.
Director of Research
Philip Morris Research Center
P.O. Box 26583
Richmond, Virginia 23261
Dear Tom:
Enclosed is a report on the psychopharmacologic effects of the N'-
substituted nicotine analogues. The drugs definitely appear to be tranquilizers,
producing mild sedation and muscle relaxation (in rats). Although they are
not as potent as the benzodiazepines (e.g. valium) they could conceivably
have anti-anxiety effects. Furthermore, they are not depressants and might
be of value in anxiety-related depression. For comparative purposes data are
presented for valium.
The preliminary tests involving only the assessment of overt behavior
following IP and intraventricular adminsitration. When more material is
available we can determine its anti-reserpine effect, prolongation in barbit-
urate sleeping time, interacting with catecholaminergic systems, etc.
You may wan,t to consider applying for patent for this class of compounds,
since they are chemically unique and may possess some novel psychotherapeutic
effects. Perhaps we can discuss this matter further at my next visit April
12, 13, 1983.
Enclosed are abstracts of a ACNP meeting that may be of interest to
you.
Sincerely,
~;F"
Leo G. Abood
LGA:ca
~.~
~
W.

-
CR #
Structure Dose (IP)
mg/kg
Sedation Body
Tone Tranquilization
(IVC) 50 pg
~o~~ ~ ~ ~,CK3 5 + +
2226 ~ 10 ++ + ++f~:
20 +++ ++
C 10 + +
2229 N'~ ~N 20 ++ ++ ~~
'~-
~-~ 10 + +
-
2233
~,1 o ~CHj
20
+
+ 7ZT
~
~----
,
10 .
0
0
2228 fC , `t4 20 + 0 4+.+
~l 10 0 0
2213 ~n
~ hl~{, 20 + 0 ~ ~
~ 10 + 0
2250 ~~',~~. ~ ~.
~ 20 ++ ++ ~ ,
10
- 0 0
20 ++ + 4+
1g _l 0 0 +
2282
- C0 ~ ~o '
N ~f~~ 2 + +
Tranquilizing effects of various CR compounds in ra $ after intraperitoneal
and intraventricular administration. ~000127514
"Sedation" was determined by measuring locomotion in an open field maze and
the response to noxious (air blast) stimuli. "Body time" was estimated by
handling rats and ability to hang from a rotor-bar.
"Tranquilization" after IVC injection was estimated from muscle weakness in
all four limbs, body tone, an& general activity.
Rating scale was 0 - l+H. For comparative purposes, a dose of 5 mg/kg valium
(IP) will have ++F+ in sedation and body tone, while 10 wg IVC will have a f+F+
in tranquilization. The duration of action of the CR drugs was 10-20 minutes
IVC and about 30 minutes after IP injecti'on.
